A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Berberine ursodeoxycholate has been studied for its serum lipid and lipoprotein lowering effects. Here the authors report an 18-week phase 2, randomised, double-blind, placebo-controlled clinical trial that tested the effect of berberine ursodeoxycholate in patients with fatty liver disease and diab...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Stephen A. Harrison, Nadege Gunn, Guy W. Neff, Anita Kohli, Liping Liu, Abbey Flyer, Lawrence Goldkind, Adrian M. Di Bisceglie
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Q
Accès en ligne:https://doaj.org/article/13c7aeb937eb489ca602dac9be76c850
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!